THE SMARTER E EUROPE 2022: INNOVATIVE SOLUTIONS FOR THE ENERGY TRANSITION AND SECURITY OF SUPPLY
30.3.2022 11:05:00 EEST | Business Wire | Press release
Independence from fossil fuels is key for climate protection – and is of relevance for security policy in light of Russia’s war in Ukraine. Europe must make enormous strides towards renewable energies in order to achieve climate targets and ensure security of supply. At The smarter E Europe – Europe's largest platform for the energy industry – 1,450 exhibitors will present innovative products and solutions to 50,000 trade visitors over an exhibition area of 132,000 m2 from May 11 to 13 in Munich.
Rising electricity and gas prices and dependence on Russian gas are giving the energy transition a tailwind. The transition is urgently needed, and possible: photovoltaics (PV) have been successful for two decades, the energy storage industry has been gaining traction for ten years, and electromobility and charging infrastructure are booming. The solutions for an independent energy supply are ready - now it is time to deploy them sustainably. Renewable energy, decentralization, digitalization, sector coupling, smart and networked energy systems as well as smart charging systems and e-mobility are the focus of The smarter E Europe 2022. Another key topic is green hydrogen. At the exhibition, the “Green Hydrogen Forum & Expo” will provide important impetus for bringing hydrogen, fuel cells, electrolysis and power-to-gas technology to the markets at an accelerated pace.
Focus on energy and mobility transition
The smarter E Europe includes four energy exhibitions: Intersolar Europe, ees Europe, Power2Drive Europe and EM-Power Europe. At Intersolar Europe, companies will present cell concepts and modules as well as inverters and solutions for building-integrated PV, agri-PV (simultaneous land use for agriculture and electricity production using PV systems) and floating PV systems. However, solar power alone does not make an energy transition; rather, what is needed is integrated solutions for a full supply of renewable energy 24/7 and across all seasons. The focus of ees Europe 2022 will therefore be on storage technologies, and in particular battery storage and green hydrogen.
Renewable energy and interconnected energy systems are closely linked to the goal of climate neutrality and the need to reassess security of supply. EM-Power Europe will therefore present smart grid solutions, smart buildings and neighborhoods, and digital business models for municipal utilities and energy providers. Power2Drive Europe will demonstrate the interconnectedness of new energies and mobility and explore everything related to the mobility of the future. This includes in particular intelligent charging solutions, vehicle-to-grid technologies, solar charging infrastructure and e-vehicles.
On May 10 – the day before the exhibition opens – visitors to the accompanying specialist conferences will discover all facets of the new energy world. In the evening, the industry innovation drivers will be honored with the Intersolar AWARD, the ees AWARD and The smarter E AWARD. Exhibition forums and workshops will bring visitors together with key industry representatives.
The smarter E Europe, which encompasses the four individual exhibitions will take place from May 11–13, 2022, at Messe München.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220329005519/en/
Contact information
Contact:
Solar Promotion GmbH | PO Box 100 170 | 75101 Pforzheim
Horst Dufner | Tel.: +49 7231 58598-0 | Fax: +49 7231 58598-28
dufner@solarpromotion.de
Press contact:
fischerAppelt, relations | Otl-Aicher-Str. 64 | 80807 Munich
Felizia Rein| Tel. +49 89 74 74 66 40
felizia.rein@fischerappelt.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release
Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom